Venus Remedies Limited has received a significant regulatory boost with the United States Food and Drug Administration (US FDA) granting Qualified Infectious Disease Product (QIDP) designation to its novel antibiotic formulation VRP-034. This designation, under the Generating Antibiotic Incentives Now (GAIN) Act, offers substantial benefits, including priority review, fast-track status, and five additional years of market exclusivity upon approval.
About VRP-034
VRP-034 is a novel supramolecular cationic formulation of polymyxin B sulfate, specifically developed to combat bloodstream infections caused by polymyxin B-susceptible strains in adults. It aims to minimize nephrotoxicity, a severe side effect associated with traditional polymyxin therapies, without compromising efficacy.
Key preclinical findings include:
- Up to 70% reduction in nephrotoxicity compared to existing PMB formulations.
- Strong efficacy against resistant pathogens in both lab and animal models.
- Favorable safety profile confirmed through advanced biomarker and organ-on-a-chip technologies.
Company’s R&D Edge
Developed by the Venus Medicine Research Centre (VMRC), the company’s proprietary Renal Guard technology was pivotal in achieving the innovative formulation. This uses kidney-on-a-chip models to study real-time kidney injury biomarkers.
CEO Statement
Saransh Chaudhary, CEO of VMRC, said, “Receiving QIDP designation is a pivotal milestone in our fight against antimicrobial resistance and validates the strength of our scientific approach.”
The development reinforces Venus Remedies’ position as a key player in critical care injectables and highlights its focus on addressing global unmet needs in infectious disease therapies.